SYNAIRGEN PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.49 GBX | -1.52% |
|
-3.85% | +8.62% |
| 2023 | FTSE 100 Finishes Slightly Lower After Steady Session | DJ |
| 2023 | Synairgen names Phytome's Joseph Colliver as CFO | AN |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 13.07M 16.33M 22.32M |
|---|---|---|---|---|---|
| Net income 2023 * | -9M -11.24M -15.37M | Net income 2024 * | - | EV / Sales 2023 * | - |
| Net Debt 2023 * | 650K 812K 1.11M | Net Debt 2024 * | 5.5M 6.87M 9.39M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-1.35
x | P/E ratio 2024 * |
-
| Employees | 34 |
| Yield 2023 * |
92.4% | Yield 2024 * |
108% | Free-Float | 96.91% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | -1.52% | ||
| 1 week | -3.85% | ||
| Current month | +27.38% | ||
| 1 month | +25.53% | ||
| 3 months | +10.47% | ||
| 6 months | -11.03% | ||
| Current year | +8.62% |
1 week
6.00
7.48
1 month
4.5010.00
Current year
4.0010.00
1 year
4.0011.30
3 years
4.00223.80
5 years
4.00260.00
10 years
4.00260.00
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
Joseph Colliver
DFI | Director of Finance/CFO | 43 | 11-05 |
Marcin Mankowski
CTO | Chief Tech/Sci/R&D Officer | - | 23-10-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Shaw
CHM | Chairman | 59 | 03-05-31 |
Stephen Holgate
FOU | Founder | 77 | 03-05-31 |
Richard Marsden
CEO | Chief Executive Officer | 57 | 03-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6.49 | -1.52% | 203,677 |
| 24-04-25 | 6.59 | +2.97% | 196,136 |
| 24-04-24 | 6.4 | -8.83% | 863,427 |
| 24-04-23 | 7.02 | +4.00% | 30,505 |
| 24-04-22 | 6.75 | 0.00% | 64,104 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotes
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
Calendar
2024-09-25
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0649
GBP
Average target price
0.4
GBP
Spread / Average Target
+516.33%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.62% | 16.28M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SNG Stock
